Logo of jester cap with thought bubble.

Image source: The Motley Fool.

Oncternal Therapeutics, Inc. (ONCT 1.38%)
Q1 2022 Earnings Call
May 05, 2022, 5:00 p.m. ET

Contents:

  • Prepared Remarks
  • Questions and Answers
  • Call Participants

Prepared Remarks:


Operator

Greetings and welcome to Oncternal Therapeutics, Inc. third quarter 2022 financial results call. [Operator instructions] It is now my pleasure to introduce your host, Richard Vincent, chief financial officer. Thank you.

You may begin.

Rich Vincent -- Chief Financial Officer

Thank you, Doug. Good afternoon, everyone, and thank you for joining us today as we cover our first quarter 2022 earnings. Joining me on the call this afternoon are our president and CEO, Dr. James Breitmeyer; and our CMO, Dr.

Salim Yazji. Today's call includes a business update and discussion of our 2022 first quarter financial results, which will be followed by Q&A. Today's press release and a replay of today's call will be available on the investor relations section of Oncternal website for at least the next 30 days. We filed our 10-Q for the first quarter 2022 earlier today as well.

10 stocks we like better than Oncternal Therapeutics, Inc.
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* 

They just revealed what they believe are the ten best stocks for investors to buy right now... and Oncternal Therapeutics, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of April 7, 2022

Please note that certain information discussed on today's call is covered under the safe harbor provisions of the Private Securities Litigation Reform Act. We will be making forward-looking statements during this call about future events such as our business and this and product development strategies, the timing of initiation of our preclinical and clinical studies, the potential for our ZILO-301 study to support a BLA submission, the timing of planned interim data updates, and the timing of our regulatory filings and submissions. Our actual results could differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with our business. These forward-looking statements should be considered in conjunction with, and are qualified by the cautionary statements contained in today's press release and our SEC filings, including our Form 10-K for the full year ended December 31, 2021.

This call contains time-sensitive information that is accurate only as of the date of this live broadcast, May 5, 2022. We undertake no obligation to revise or update any forward-looking statements to reflect the events or circumstances occurring after the date of this call. With that, it is my pleasure to hand the call over to our CEO, Dr. Jim Breitmeyer.

Jim Breitmeyer -- Chief Executive Officer

Thank you, Rich, and good afternoon, everyone. At Oncternal, we are advancing a focused and robust product pipeline with clinical and pre-clinical product candidates that target cancers for patients with unmet medical needs. During the first quarter of 2022, we further sharpened our focus on the achievement of key pipeline catalyst in immunologic malignancies in prostate cancer as we navigated an unprecedented challenging macro environment, which is obviously continuing in the second quarter, including today's stock market events. We made significant progress toward the initiation of our global phase 3 registrational study, ZILO-301, for zilovertamab in patients with mantle cell lymphoma, which is planned to be initiated in the third quarter of 2022.

Zilovertamab is our investigational, potentially first-in-class humanized monoclonal antibody that inhibits receptor tyrosine kinase, like orphan receptor 1, or ROR1, function by binding with high affinity to a biologically important epitope on the receptor. We continue to evaluate additional countries in study sites for the phase 3 study to ensure robust enrollment as we mitigate disruptions caused by the situation in Ukraine. As a reminder, we reached consensus with the FDA on the design and major details of the ZILO-301 study plan, which is supported by encouraging data from our ongoing phase 1/2 clinical trial of zilovertamab in combination with ibrutinib, the CIRLL study. We look forward to providing a data update on that study at this year's American Society of Clinical Oncology Meeting in Chicago in June 2022.

Our autologous CAR-T cell pro program targeting ROR1, ONCT-808, also continues to advance and is on track for an IND filing in mid-2022. In our initial phase 1 study, we plan to enroll patients with relapsed or refractory hematologic malignancies, including those who have failed CD19 CAR-T cell therapy. We established a clinical manufacturing agreement with the Dana-Farber Cancer Institute to conduct collaborative CGMP process development and manufacturing activities for use in our upcoming first-in-human studies. Our partners at the Dana-Farber have some of the best cell manufacturing facility in the world and proved to be a perfect fit with the cell processing technology we selected for our ROR1 CAR-T program.

Research collaborations with Cellularity and with the Karolinska Institute continue to generate encouraging data for our other next generation off-the-shelf ROR1-based cell therapy program. Next, ONCT-534, the lead candidate of our dual-action androgen receptor inhibitor, or DAARI program, continues to advance toward IND-enabling studies. ONCT-534 may be a highly differentiated and novel treatment alternative for patients with advanced prostate cancer as we believe it interacts with both the end terminal and the ligand binding domains of the androgen receptor, inhibiting its function and inducing its degradation. Pre-clinical data have shown that ONCT-534 exerts anti-tumor activity in clinically relevant prostate cancer models, including those with AR amplification, enzalutamide resistance, or tumors expressing androgen receptor splice variants, such as AR-V7, all of which represent significant unmet medical needs for patients with prostate cancer.

Finally, we announced the deep prioritization of development of our E26 transformation-specific, or ETS, inhibitor, ONCT-216, along with the discontinuation of enrollment in the phase 1/2 study, evaluating ONCT-216 in patients with relapsed or refractory Ewing sarcoma. This resource reallocation will allow us to further focus on hematologic malignancies and prostate cancer while deploying our capital toward meaningful catalysts, especially those related to our lead asset, zilovertamab. Let me now turn the call back to Oncternal CFO, Rich Vincent.

Rich Vincent -- Chief Financial Officer

Thank you, Jim. Our grant revenue is derived from a California Institute for Regenerative Medicine, or CIRM, grant sub award and two research and development grants from the National Institutes of Health or NIH. In October 2017, CIRM awarded an $18.3 million grant to researchers at the UC San Diego School of Medicine to advance our CIRLL study. We are conducting this study in collaboration with UC San Diego and expect to receive approximately $14.4 million in development milestones under research sub awards throughout the award period that was substantially completed from a revenue perspective in the first quarter of 2022.

In the third quarter of 2021, the NIH awarded the company two research and development grants for up to $2.2 million to support preclinical activities for the company's ONCT-534 and ONCT-216 programs, including 0.7 million that is payable to sub awardees. Our grant revenue was $0.7 million for the first quarter ended March 31, 2022. Our total operating expenses for the first quarter ending March 31, 2022, were 10.7 million, including 2 million in noncash stock-based compensation expense. Research and development expenses totaled 7 million, and general and administrative expenses totaled 3.7 million.

Net loss for the first quarter was 9.9 million, or a loss of $0.20 per share, basic and diluted. As of March 31, 2022, we had 82.2 million in cash and cash equivalents and no debt. We believe these funds will be sufficient to support our operations well into the third quarter of 2023. We have and will continue to manage expenses deliberately and will explore all potential sources of capital to enable us to reach our milestones.

As of March 31,2022, we had 49.4 million shares of common stock outstanding. With respect to upcoming milestones for our zilovertamab program, we expect to initiate the global registrational phase 3 study, ZILO-301, in the third quarter of 2022. We expect to report an interim clinical data update for patients with MCL and CLL treated with zilovertamab plus ibrutinib from our ongoing CIRLL study at the June 22 ASCO meeting. We also expect to have a phase 1b investigator-sponsored trial of zilovertamab plus docetaxel, enrolling patients with metastatic castration-resistant prostate cancer in mid-2022.

On the cell therapy front, we are on track to submit our first IND for ONCT-808, our autologous ROR1 CAR-T cell candidate in mid-2022. For ONCT-534, our lead DAARI product candidate, we are on track to initiate IND-enabling GLP toxicology studies and GMP manufacturing in the second quarter of 2022. Now, I will turn the call back over to Jim.

Jim Breitmeyer -- Chief Executive Officer

Thank you, Rich. We look forward to multiple catalysts in 2022, especially the initiation of our global phase 3 zilovertamab study and submitting our ROR1 CAR-T IND application, and advancing our DAARI program toward the clinic. Our sharp focus on resource allocation, prudent cash management, and the strong balance sheet are enabling us to navigate this historically challenging macro environment. We plan to continue to focus our resources on areas of the highest unmet patient need, where we believe our product candidates can make the greatest difference for patients.

Thank you for joining us today and we look forward to updating you during upcoming medical and banking conferences. With that, I will turn things back to Doug for the Q&A portion of this afternoon's call and remind you that CMO Salim Yazji is also on with us for the Q&A.

Questions & Answers:


Operator

[Operator instructions] Our first question comes from the line of Hartaj Singh with Oppenheimer. Please proceed with your question.

Hartaj Singh -- Oppenheimer and Company -- Analyst

Great. Thank you. Thanks for the update, Jim and team. And just a couple of quick questions.

Jim, I know that when you presented, and Salim and everyone had presented the phase 3 design for zilovertamab-301 a couple of months ago, you'd also talked about a ZILO-302 aspect to that. How are you thinking about that? That's the -- I guess that's beyond for the patients that have progressive disease, the run-in patients on ibrutinib. So, just what are you thinking about that? And I just got a couple of quick follow-up questions after that.

Jim Breitmeyer -- Chief Executive Officer

Sure. I'll start, and Salim can comment as well. The 302 study you're referring to is one of the really novel aspects of our registration study design because during the four month running or enrichment portion of the study, where patients receive single agent ibrutinib, a percentage of those patients will progress on ibrutinib. And so they're already in our study.

They're already well-documented with disease parameters and medical history and everything. And so, to give them the opportunity to see if their disease can be resensitized to ibrutinib with zilovertamab therapy, it's a very convenient and incrementally inexpensive way to test for impact of zilovertamab in this resistant disease. So, we're still planning to conduct that part of the study as well. And since it's open label, that would also give us an opportunity to talk about the results in real time on our medical conferences than having to wait for the blind to be broken in the main 301 study.

Salim, do you want to add anything to that?

Salim Yazji -- Chief Medical Officer

No, I think you summarized it very well, Jim. That's good.

Hartaj Singh -- Oppenheimer and Company -- Analyst

Great. And then the other question I would have is just, you know, on ONCT-808, the CAR-T therapy, you know, Jim and Salim, if you can just kind of describe once you file the IND in mid-2022, what's the sort of clinical program, you know, setups that we can look forward to? I mean, bucket study, certain tumor types, you know, hematology versus solid tumor, just what are your thoughts on that could look like in the second half of this year?

Jim Breitmeyer -- Chief Executive Officer

Go ahead, Salim.

Salim Yazji -- Chief Medical Officer

Yeah. So, Hartaj, this just will be mainly in hematologic malignancies as a first-in-human study. And specifically, we're going to do a dose escalation in lymphoma, B-cell lymphoma patients. Once we reach our recommended phase 2 portion, then we can expand to other cohorts as well.

Hartaj Singh -- Oppenheimer and Company -- Analyst

Got it, Salim. So, I mean, just so I'm clear, it'll be hematologic malignancies but the cohorts, meaning you just -- you have a bucket of patients with different types of tumor types and then picked the ones you want to dose expand into Optune, get into your recommended phase 2 dose?

Salim Yazji -- Chief Medical Officer

In the dose escalation, we will have only B-cell lymphoma, including diffuse large B-cell lymphoma, MCL, and maybe excessive lymphomas. That's in the dose escalation. Now in the expansion cohorts, we will expand in those patient population for sure, but also, we may open, you know, other indication in hematological malignancies, like maybe example multiple myeloma, or others.

Hartaj Singh -- Oppenheimer and Company -- Analyst

And, Salim, is there any sort of pathway that you see with the CAR-T program whereby there's some tumor type you're looking at where the unmet need is high enough that, you know, if you see a good signal in dose escalation and you get into dose expansion that that could actually form the basis for potential accelerated approval type scenario? I know that's low probability, but just any thoughts there?

Salim Yazji -- Chief Medical Officer

Yeah. Absolutely. I mean, I think we -- as you know, since this is going to be, again, dose escalation, open label, we're going to be looking into signal as we go. And, you know, if we see that something could be possibility to get a quick approval, or escalated approval, we will go after that for sure.

Hartaj Singh -- Oppenheimer and Company -- Analyst

Yeah. And these will be patients that are later lined in general therapy than what the ROR1 antibody would have seen, right? Zilovertamab would have seen?

Salim Yazji -- Chief Medical Officer

Yeah, absolutely, And as Jim mentioned, this will be in relapsed refractory hematological malignancy, which is probably a little bit later line of therapy, including patients who have failed CD19 CAR-T, where there is a huge unmet medical need there as well.

Hartaj Singh -- Oppenheimer and Company -- Analyst

And then last question. Just -- when you see filing the IND for ONCT-534?

Jim Breitmeyer -- Chief Executive Officer

So, we haven't guided to the timing of that IND yet, Hartaj. And the reason is that like other people, we're experiencing some supply chain uncertainty, including things such as slots for manufacturing activities and availability of animals and equipment for toxicology studies. So, this is an area where there's still some continuing impact from COVID. So, we just haven't been specific yet.

And when we have greater clarity around timing of the IND enabling work, then we will make an -- we will lay that out.

Hartaj Singh -- Oppenheimer and Company -- Analyst

Great. That makes sense, Jim. Thank you all for the update. Really appreciate it.

Jim Breitmeyer -- Chief Executive Officer

Thank you.

Operator

Our next question comes from the line of Carl Byrnes from Northland Capital. Please proceed with your question.

Carl Byrnes -- Northland Securities -- Analyst

Thanks for the question, and congratulations on your progress. With respect to ZILO-301 and 302 studies, how many sites do you anticipate recruiting or participating in those studies? I think before, you were looking at around 50. And I guess my question is, has that changed given what's going on in Eastern Europe? Thanks.

Jim Breitmeyer -- Chief Executive Officer

Go ahead, Salim.

Salim Yazji -- Chief Medical Officer

Yes, I think we're monitoring this situation very closely. And, you know, the short answer is yes, we are trying to look into additional sites. And especially, Eastern Europe now it's kind of a little bit, you know, difficult to recruit there. So yes, we may go little bit beyond that.

Yeah.

Carl Byrnes -- Northland Securities -- Analyst

Great. Thanks. That's helpful.

Jim Breitmeyer -- Chief Executive Officer

Thank you, Carl.

Operator

Our next question comes from the line of Kaveri Pohlman with BTIG. Please proceed with your question.

Unknown speaker

Hi. Thanks. Good afternoon. This is Brian for Kaveri.

And thanks for the update and thanks for taking our question. Just one from me regarding the use of zilovertamab in CRPC. Is the Wnt5a signaling pathway providing the main biology and rationale for this trial? And is it really ROR1 driven? Our understanding is that ROR2 is also our receptor for Wnt5a. Thank you.

Jim Breitmeyer -- Chief Executive Officer

Hi, Brian. And thank you for standing in for Kaveri today. So, the ROR1 and ROR2 can actually form a heterodimer, which can act as a receptor for Wnt5a. And so the ROR2 is, for us, kind of in the background.

We're not targeting it because, first of all, our antibody doesn't target ROR2. And it's also harder to target ROR2 selectively on tumors because it has a broader distribution on normal tissues. So, the ROR1 is highly expressed on prostate cancer. That's part of the rationale.

The other is a very interesting data out of UC San Diego that shows that in the bone tumor micro environment, the prostate cancer bone metastasis, that Wnt5a is one of these absolutely most highly over expressed proteins. And so, we see the receptor for Wnt5a. We see Wnt5a. And that forms a nice rationale for prostate cancer.

Unknown speaker

Excellent. Thank you so much for the very thorough answer, and thanks for the questions.

Jim Breitmeyer -- Chief Executive Officer

You're welcome, Brian.

Operator

Our next question comes from the line of Kumar Raja with Brookline Capital Markets. Please proceed with your question.

Shubhendu Sen Roy -- Brookline Capital Markets -- Analyst

Hi. I'm Shubhendu for Kumar. Thanks for the update. Could you provide some color to the 216 program? What is the strategy there to take it further? I mean, are you exploring collaborations or partnerships? And also, there were two patients that demonstrated CR, how are they doing now? And are there any other patients that are showing a similar response? Thank you.

Jim Breitmeyer -- Chief Executive Officer

I'll let Salim comment on the patients first.

Salim Yazji -- Chief Medical Officer

Yeah. So, we still have, you know, two patients that are still in CR. One has been off treatment and continues to be in CR after eight months of therapy. And the other patient is still on CR on therapy.

And we're going to continue giving the drug to these patients and maybe a compassionate use program since the CR is still durable.

Jim Breitmeyer -- Chief Executive Officer

Yes. And so as far as the program is concerned, we have, as we've announced, we're focusing our clinical programs particularly on the zilovertamab phase 3 study. However, we do have an NIH grant with which we're collaborating with some academic investigators, including the discover of this form of ETS inhibition, Jeff Toretsky, to do further work on the mechanism. The puzzle for us is that we are inducing these dramatic responses, but only in a very small percentage of cases.

And so, we feel that it's necessary to know more about the mechanism. And so, we have a nondilutive source of funding for that research. There is an open IND to continue to study TK216, ONCT-216 in China through our collaborator, Shanghai Pharma. And we expect that study to -- in Ewing sarcoma to open soon.

And we expect they'd be doing some additional biomarker work and such to try to understand mechanistically what's occurring.

Shubhendu Sen Roy -- Brookline Capital Markets -- Analyst

Thank you. That is useful. And also, what's the cutoff date going to be for the phase 1/2 ASCO to be carried out? And how many patients do you expect to include in that? And what are the expectations in terms of point to points, like progression for survival and so on. Thank you.

Jim Breitmeyer -- Chief Executive Officer

Were you asking the cutoff date?

Shubhendu Sen Roy -- Brookline Capital Markets -- Analyst

Yeah.

Jim Breitmeyer -- Chief Executive Officer

So, as you can imagine, you know, the posters are due to ASCO on May 16th. And so, we've tried to go as late as we can and still process the information. The contents of what we're going to present are still embargoed by ASCO. But there would be updated information compared to the ASH Meeting for both CLL and mantle cell, including a more mature look at progression-free survival and also further look at interesting subset analyses.

Shubhendu Sen Roy -- Brookline Capital Markets -- Analyst

OK. Thanks. And finally, just regards to the Dana-Farber collaboration, could you please provide some color to the kind of agreement this is? And, you know, any other details with regards to the kind of capacity they have and the timelines of manufacturing? And when do you think you'll have the first batch ready? Thank you.

Jim Breitmeyer -- Chief Executive Officer

Thank you. So, it's a collaboration and manufacturing agreement. And you may recall that we're using a bench-top processing system called the Miltenyi Prodigy, and that's technology that the group at the Dana-Farber have quite a bit of experience with, and they own their own Prodigy equipment. And so, we expect that by the times that we submit our IND, that several performance-characterizing runs will have been performed at the Dana-Farber and that they will be ready to manufacture as soon as sites are open and able to enroll patients.

There will be -- they have indicated that they can handle capacity, both from sites in the Harvard system and sites outside of Massachusetts. And so, we're very happy with their apparent capacity here for our phase 1 program.

Shubhendu Sen Roy -- Brookline Capital Markets -- Analyst

Thank you so much for taking my questions.

Jim Breitmeyer -- Chief Executive Officer

Thank you for your questions. We appreciate your call today.

Operator

There are no further questions in the queue. I'd like to hand the call back to management for closing remarks.

Jim Breitmeyer -- Chief Executive Officer

Thank you, everybody. This is Jim Breitmeyer. And so, on behalf of Richard Vincent, Salim Yazji, and everyone in Oncternal, I thank you for your interest and participation today. Have a good day, and we look forward to catching up with you in the future.

Operator

[Operator signoff]

Duration: 29 minutes

Call participants:

Rich Vincent -- Chief Financial Officer

Jim Breitmeyer -- Chief Executive Officer

Hartaj Singh -- Oppenheimer and Company -- Analyst

Salim Yazji -- Chief Medical Officer

Carl Byrnes -- Northland Securities -- Analyst

Unknown speaker

Shubhendu Sen Roy -- Brookline Capital Markets -- Analyst

More ONCT analysis

All earnings call transcripts